GPNMB Expression is Associated with WORSE Prognosis in Renal Cell Carcinoma
No, there is no research showing GPNMB is associated with better prognosis in RCC—the evidence consistently demonstrates the opposite: high GPNMB expression predicts poor outcomes, extensive metastasis, and reduced survival.
Evidence for Poor Prognosis
The available research uniformly indicates that GPNMB overexpression correlates with aggressive disease and unfavorable outcomes in clear-cell renal cell carcinoma (ccRCC):
Primary Findings on Survival and Metastasis
Elevated GPNMB expression independently predicts poorer overall survival in primary ccRCC 1. In a study of 43 primary ccRCC cases, Kaplan-Meier analysis demonstrated that patients with high GPNMB expression had significantly worse outcomes, and multivariate analysis confirmed GPNMB as an independent risk factor for poor prognosis 1.
The metastatic potential is particularly concerning. GPNMB expression levels are significantly higher in metastatic ccRCC compared to matched primary tumors (P=0.036), suggesting that tumor cells expressing high GPNMB levels have enhanced capacity for metastasis 1.
Bone Metastasis Association
In patients with bone metastases, GPNMB overexpression is significantly associated with both the number and extent of bone metastasis (P=0.001 for both), as well as higher Fuhrman grade (P=0.037) 2. Among 31 RCC patients with bone metastases, those with high GPNMB expression had significantly worse overall survival (P=0.001) 2.
Biological Mechanism
The poor prognosis appears mediated through specific pathways:
- GPNMB promotes tumor cell migration, invasion, and metastasis in ccRCC 1
- Knockdown of GPNMB in RCC cell lines suppresses proliferation, migration, and invasion 2
- These effects are likely mediated through the ERK signaling pathway, as GPNMB downregulation reduces phosphorylated ERK expression 2
Clinical Implications
GPNMB as a Prognostic Marker
GPNMB should be considered a marker of high-risk disease rather than favorable prognosis. Receiver operating characteristic (ROC) curve analysis has been used to establish cutoff scores for GPNMB expression that can stratify patients by risk 1.
Potential Therapeutic Target
Rather than being a favorable prognostic marker, GPNMB represents a potential therapeutic molecular target for aggressive RCC, particularly in patients with metastatic disease or bone metastases 1, 2.
Important Caveats
While GPNMB is expressed in certain renal tumor subtypes (such as TFE3-rearranged RCC 3 and low-grade oncocytic tumors 4), this expression pattern serves as a diagnostic marker for tumor classification, not a prognostic indicator of favorable outcomes. The prognostic significance specifically relates to its role in promoting metastasis and aggressive behavior in ccRCC.
Current guidelines do not include GPNMB in routine prognostic assessment 5, 6, as established risk stratification systems (KEYNOTE-564 classification for localized disease, IMDC for advanced disease) remain the standard 6.